Biotech entity
The clearest coverage concentration is pharma: 17 of 20 stories, with the rest divided among 2 other categories. Of the tracked stories, 13 of 20 also mention Weiss Ratings, the most common co-covered peer. Negative sentiment reaches 0% here, compared with 18% across the 686-story beat baseline for the same window.
Last mentioned: Sep 9, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
The clearest coverage concentration is pharma: 17 of 20 stories, with the rest divided among 2 other categories. Of the tracked stories, 13 of 20 also mention Weiss Ratings, the most common co-covered peer. Negative sentiment reaches 0% here, compared with 18% across the 686-story beat baseline for the same window. Each story carries 2.1 original sources on average, compared with 3.5 for the broader beat in this window. The 5 average consequence score is below the beat benchmark of 6.1 in the same window. Across a 195-day span, the pace is roughly 0.7 stories per week. The busiest single day carried 2. This profile follows 20 Biotech stories mentioning Wall Street Zen across the period from February 27, 2026 to September 9, 2026.
Computed from the 20 stories linked to this entity, with beat comparisons drawn from all 686 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Wall Street Zen. Shared-story counts are live from our verified record — not editorial picks.
Wall Street Zen rating actions
Wall Street Zen upgraded Tenaya from strong sell to sell and argenx from hold to buy.
Deutsche Bank downgrades argenx
Deutsche Bank cut argenx from buy to hold.
Wall Street Zen upgrades both stocks to Hold
Wall Street Zen upgraded CTNM and ENVB from Sell to Hold in Sunday research notes.
Truist raises argenx target
Truist Financial lifted its argenx target from $1,030.00 to $1,095.00 with a buy rating.
Quarterly earnings release
Lantern Pharma reported quarterly EPS of ($0.57), missing consensus by $0.19; shares rose $0.02 to $2.65.
Enveric reports quarterly loss
Enveric Biosciences reported EPS of -$0.76 for the quarter.
Q2 earnings released; EPS beats consensus
Company reported ($1.40) EPS versus ($1.55) consensus; shares rose $0.05 to $0.57 on 2.3x average volume
Insider sales
CEO Sushil Patel sold 39,341 shares at $12.97 and insider Konstantinos Xynos sold 11,447 shares at $12.97, both to cover tax withholding obligations.
Wedbush upgrade
Wedbush upgraded Replimune Group from neutral to outperform and set a $12.00 price target.
Tenaya Q2 miss
Tenaya reported EPS of -$0.20 versus -$0.07 expected and revenue of $1.11 million versus $10 million consensus.
Leerink upgrade
Leerink Partners upgraded Replimune Group from market perform to outperform and raised its price target from $11.00 to $17.00.
RBC raises CTNM target to $23
Royal Bank of Canada raised its Contineum target from $22.00 to $23.00 with an Outperform rating.
Contineum reports Q2 results
Contineum reported Q2 EPS of -$0.40, beating consensus by $0.05.
Weiss Ratings upgrade
Weiss Ratings upgraded Lantern Pharma from 'sell (e+)' to 'sell (d-)'.
Baird raises argenx target
Robert W. Baird raised argenx target from $867.00 to $932.00 with a neutral rating.
argenx Q2 beat
argenx reported EPS of $7.32 versus $5.86 expected and revenue of $1.54 billion.
Weiss Ratings reiterates Sell
Restated a 'sell (e+)' rating on MBRX shares in a research note
Shares drop 1.8%
APYX traded as low as $4.34 and last at $4.38 on volume of 43,859 shares, 60% below average.
BofA lifts argenx target
Bank of America raised its price objective on argenx from $1,016.00 to $1,088.00 with a buy rating.
Clinical Catalyst
Anticipated data readouts for sevasemten in Becker Muscular Dystrophy trials.
Wall Street Zen upgraded Tenaya from strong sell to sell, but the micro-cap gene therapy company still trades near a 52-week low after a sharp Q2 EPS and revenue miss. Biotech readers get a closer look at how clinical-stage execution failures are reflected in rating actions, while argenx's profitable rare disease business shows what commercial success looks like.
Source: tickerreport.com · dailypolitical.com
A rare double upgrade by Wall Street Zen moved Contineum Therapeutics and Enveric Biosciences from Sell to Hold, offering a momentary reprieve for two money-losing clinical-stage biotechs. CTNM trades near its 52-week high at $17.19 with a $20.25 consensus target, while ENVB's psychedelic pipeline carries a $6.41M market cap against a former $17.64 high.
Source: themarketsdaily.com · tickerreport.com
Clinical-stage Moleculin Biotech is now valued at just $4.06 million after a 97% collapse from its 52-week high, raising existential questions about its ability to fund development of therapies for resistant tumors and viral infections. The EPS 'beat' of ($1.40) versus ($1.55) is a paper figure — no revenue, cash balance, or clinical milestone accompanied the report.
Source: dailypolitical.com · themarketsdaily.com
Replimune reported ($0.72) EPS, missing by $0.03, but for biotech investors the quarter is a side note to pipeline catalysts and analyst upgrades. Insider sales were tax-related, and recent price targets of $16 to $17 suggest confidence in the oncolytic immunotherapy platform.
Source: tickerreport.com · themarketsdaily.com
Lantern Pharma's $0.57 quarterly loss missed consensus by $0.19, underscoring clinical-stage risk. The micro-cap oncology company has no product revenue, and analysts maintain a Sell rating. Biotech investors need clarity on cash runway and upcoming trial catalysts.
Source: dailypolitical.com · themarketsdaily.com
For biotech and pharma investors, Apyx Medical's Q1 loss of $0.05 per share beat consensus by $0.06, but the stock fell 1.8% to $4.38 on low volume. Mixed analyst ratings and a $6.50 consensus target raise questions about whether the small-cap device maker can convert clinical and operational beats into stock appreciation. Institutional repositioning signals ongoing evaluation of the company's commercial ramp.
Source: dailypolitical.com · tickerreport.com
SCYNEXIS shorts collapsed 87.6% to 320,181 shares, signaling bear exhaustion, while Ensysce Biosciences short interest exploded 619.9% to 364,278. Focus Universal also saw a 282.8% build, reflecting a stark divergence in microcap biotech sentiment.
Source: tickerreport.com · dailypolitical.com
A corporate insider at microcap HCW Biologics disclosed a $19,958.88 purchase of 7,736 shares at $2.58, but conflicting syndicated reports name different insiders. For biotech investors, the transaction highlights a high-risk stock trading 93% below its 52-week high despite a May EPS beat and a $30 Maxim target.
Source: themarketsdaily.com · dailypolitical.com
Palvella Therapeutics stock sank 12.4% Monday with no news, highlighting biotech liquidity risk. Analyst consensus target of $199.53 implies 45% upside, but earnings miss and two sell ratings complicate the picture for biotech investors.
Source: dailypolitical.com · tickerreport.com
Analyst action pushes Talphera into the spotlight as a deeply undervalued biotech, with a $3.00 average target offering over 100% upside. Recent earnings beat and institutional buying add to the narrative. Two buy initiations from specialized firms highlight confidence in the pain management pipeline.
Source: themarketsdaily.com · dailypolitical.com
Short interest in CDT Equity, the ticker for clinical-stage biotech Conduit Pharmaceuticals, jumped 70.8% after the stock plunged from a $610 high to just $0.71. With a market cap of $3.45 million and no approved products, the spike in bearish bets underscores the deep skepticism around its early-stage pipeline for autoimmune diseases and infertility.
Source: themarketsdaily.com · tickerreport.com
Spyglass Pharma's stock plunges to a new 52-week low of $17.56 despite a consensus 'Moderate Buy' rating and an average analyst target of $45. For biotech investors, the 156% upside potential must be weighed against a recent earnings miss and a downgrade to sell, raising questions about near-term pipeline catalysts.
Source: tickerreport.com · dailypolitical.com
Collegium Pharmaceutical's earnings beat of $0.20 per share, reaching $1.92 on $199.88M revenue, highlights its commercial success in the abuse-deterrent opioid space, a key sector for the biopharma industry.
Source: dailypolitical.com · themarketsdaily.com
Wall Street Zen upgraded biotech Agenus to buy despite a massive Q1 earnings miss, as the stock surged 189% from its 52-week low. Mixed analyst views and a $30 HC Wainwright target highlight the speculative upside in immuno-oncology.
Source: tickerreport.com · dailypolitical.com
Teva's fiscal 2026 EPS guidance, well below the Street's $2.17, raises red flags for biotech and pharma investors. However, a $42 average price target and stable revenue suggest a value play if the biosimilar pipeline delivers.
Source: tickerreport.com · themarketsdaily.com
Novavax was slapped with a sell rating by Wall Street Zen, even after beating Q1 revenue estimates by 49%. The downgrade highlights biotech skepticism toward small-cap vaccine players in a shifting market.
Source: dailypolitical.com · tickerreport.com
Wall Street Zen has downgraded SAB Biotherapeutics (SABS) and its investor SURO Capital (SSSS) to Sell ratings. The move signals increasing caution regarding SAB's clinical-stage polyclonal antibody platform and the broader venture-backed biotech ecosystem.
Source: tickerreport.com · tickerreport.com
Wall Street Zen has upgraded the stock ratings for Codexis (CDXS) and Enovis (ENOV), signaling increased confidence in their long-term strategic pivots. The upgrades follow robust quarterly performances and the unveiling of ambitious 2026 revenue targets driven by high-margin technological innovations.
Source: dailypolitical.com · themarketsdaily.com
Wall Street Zen has upgraded Organogenesis (NASDAQ: ORGO) to a 'Buy' rating, signaling increased confidence in the regenerative medicine specialist's market position. This move comes amid a broader wave of optimistic re-ratings for mid-cap growth stocks across multiple sectors, including oilfield services and software.
Edgewise Therapeutics (NASDAQ: EWTX) has reached a new 52-week high, reflecting growing investor confidence in its clinical-stage pipeline for rare muscle and cardiac diseases. The surge follows recent analyst upgrades and positive sentiment surrounding its lead candidates, sevasemten and EDG-7500.
Source: dailypolitical.com · tickerreport.com
Wall Street Zen is linked from 20 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
